Iovance Biotherapeutics price targets raised following FDA accelerated approval

  • Investing.com
  • Stock Market News
Iovance Biotherapeutics price targets raised following FDA accelerated approval
Credit: © Reuters.

Shares of Iovance Biotherapeutics (NASDAQ: IOVA ) surged more than 37% Tuesday after the company announced the FDA has granted accelerated approval to its T cell immunotherapy, Amtagvi (lifileucel) suspension, to treat advanced melanoma after anti-PD-1 and targeted therapy.

The announcement prompted several price target increases from Wall Street analysts.

H.C. Wainwright lifted its price target for the stock to $32 per share. The firm maintained its Buy rating on IOVA, stating they believe the approval of the TILs for melanoma is a "momentous occasion."

"It solidifies our original thesis of having a cellular therapy be approved in a solid tumor where CAR-Ts have continued to falter," said the firm.

Piper Sandler raised its price target for the stick to $18 from $14 per share. They said they remain Overweight on IOVA and believe the approval supports their upgrade last year, which was also contingent on FY24 looking achievable, something they believe still looks very much intact.

Finally, Baird raised its price target for Iovanace to $26 from $20 per share, maintaining an Outperform rating on the stock.

The firm said Amtagvi's price is $515,000, which is above their expectations. They believe Iovance should be "well positioned with 30 centers at launch to capture on the bolus of patients (not quantified), with revenues really starting to hit in 2Q24."

"Looking ahead, we see meaningful upside on launch execution and the long-term potential of Amtagvi," added the firm.

Add Chart to Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Drop an image here or Supported formats: *.jpg, *.png, *.gif up to 5mb

Error: File type not supported

Drop an image here or

100
Please try another search

Related Articles